▁Introduction 7.8203125
: 1.9072265625
<0x0A> 6.51953125
In 3.416015625
▁a 3.43359375
▁break 8.09375
through 1.3115234375
▁moment 4.16015625
▁in 1.6689453125
▁the 1.1171875
▁fight 4.40625
▁against 0.72412109375
▁cancer 3.30078125
, 0.11761474609375
▁British 6.1171875
▁bi 3.736328125
ote 0.640625
ch 0.31591796875
▁company 0.953125
, 1.9931640625
▁[ 9.1796875
Company 7.4609375
▁Name 1.4013671875
], 0.75
▁has 0.8095703125
▁un 3.314453125
ve 0.10479736328125
iled 0.0004410743713378906
▁a 0.833984375
▁ground 2.70703125
- 1.0458984375
bre 0.00238037109375
aking 0.00013434886932373047
▁treatment 2.4296875
▁that 0.59228515625
▁shows 4.71875
▁remarkable 3.337890625
▁potential 2.349609375
. 3.181640625
▁The 1.02734375
▁innov 3.0859375
ative 0.059417724609375
▁drug 2.56640625
▁has 2.513671875
▁already 2.22265625
▁demonstrated 2.46484375
▁prom 3.072265625
ising 0.0003268718719482422
▁results 0.06805419921875
▁in 0.19140625
▁early 1.806640625
▁clin 1.109375
ical 0.0002617835998535156
▁tri 0.017791748046875
als 0.00010764598846435547
, 0.48095703125
▁raising 3.927734375
▁hope 2.2734375
▁for 1.23828125
▁patients 2.03515625
▁and 1.537109375
▁health 3.052734375
care 0.1456298828125
▁profession 0.3125
als 4.8041343688964844e-05
▁al 0.120849609375
ike 4.5180320739746094e-05
. 0.028167724609375
▁However 5.14453125
, 0.002506256103515625
▁while 3.65234375
▁the 0.51318359375
▁initial 3.90234375
▁find 0.77734375
ings 8.976459503173828e-05
▁insp 9.1328125
ire 0.0028839111328125
▁optim 0.420654296875
ism 0.0008068084716796875
, 0.1309814453125
▁anal 8.828125
yst 0.02642822265625
s 0.003753662109375
▁stress 5.546875
▁the 1.33203125
▁need 0.480712890625
▁for 0.1265869140625
▁c 4.76171875
aut 0.0027751922607421875
ious 0.0027027130126953125
▁optim 0.331298828125
ism 0.00043702125549316406
▁and 1.7822265625
▁further 1.3544921875
▁research 0.7861328125
▁before 0.8798828125
▁fully 5.53515625
▁end 1.6640625
ors 0.00013458728790283203
ing 0.00017881393432617188
▁this 2.033203125
▁potential 2.546875
▁break 2.072265625
through 0.0005154609680175781
. 0.207763671875
<0x0A> 0.36572265625
Prom 5.15625
ising 0.041351318359375
▁C 2.962890625
lin 0.00885009765625
ical 0.0005402565002441406
▁Results 2.8828125
: 0.3212890625
<0x0A> 0.239990234375
[ 2.9765625
Company 0.0286407470703125
▁Name 0.0107574462890625
] 0.11553955078125
' 3.244140625
s 0.0007257461547851562
▁cancer 4.64453125
▁drug 1.0947265625
, 1.6796875
▁currently 3.982421875
▁in 1.16796875
▁the 2.6953125
▁experimental 5.59765625
▁stage 0.6826171875
, 0.062286376953125
▁has 0.1826171875
▁yield 3.255859375
ed 9.036064147949219e-05
▁encourag 2.103515625
ing 0.00019240379333496094
▁results 0.396728515625
▁in 0.24609375
▁pre 2.298828125
lim 0.5654296875
inary 0.0002104043960571289
▁tri 0.7998046875
als 4.1365623474121094e-05
. 0.301513671875
▁Initial 5.046875
▁data 1.6796875
▁indicates 1.81640625
▁a 3.13671875
▁substantial 3.712890625
▁reduction 0.93212890625
▁in 0.02252197265625
▁tum 0.41748046875
or 0.37109375
▁size 0.2252197265625
▁and 0.9814453125
▁improved 1.6259765625
▁surv 1.04296875
ival 0.0034999847412109375
▁rates 0.07177734375
▁among 1.7451171875
▁a 5.08203125
▁select 2.05859375
▁group 0.0718994140625
▁of 0.0019817352294921875
▁patients 0.274658203125
. 0.36669921875
▁The 1.4228515625
▁drug 0.48583984375
' 1.4404296875
s 4.374980926513672e-05
▁unique 2.71875
▁mechanism 0.2236328125
▁of 0.0206451416015625
▁action 0.004840850830078125
, 1.5068359375
▁which 0.6279296875
▁targets 0.57861328125
▁specific 1.451171875
▁cancer 1.9921875
▁cells 0.262451171875
▁while 1.1298828125
▁sp 0.78955078125
aring 4.2557716369628906e-05
▁health 0.08428955078125
y 0.0005793571472167969
▁t 0.73046875
issues 1.9365234375
, 0.0255279541015625
▁holds 3.669921875
▁significant 2.033203125
▁potential 1.0458984375
▁for 0.45654296875
▁transform 3.484375
ing 0.06658935546875
▁cancer 0.70263671875
▁treatment 0.2666015625
▁on 8.3046875
▁a 0.07257080078125
▁global 0.1510009765625
▁scale 0.056427001953125
. 0.013397216796875
<0x0A> 0.161376953125
Anal 2.826171875
yst 0.0889892578125
s 0.18603515625
▁Ur 3.796875
ge 0.0152130126953125
▁Ca 0.236083984375
ution 0.00014472007751464844
: 0.0301513671875
<0x0A> 0.01358795166015625
Des 0.80908203125
p 3.337860107421875e-05
ite 2.6226043701171875e-06
▁the 0.286865234375
▁early 2.681640625
▁success 1.0234375
, 1.3115234375
▁exper 1.5703125
ts 9.179115295410156e-06
▁remain 2.234375
▁c 0.128662109375
aut 3.0994415283203125e-05
ious 0.046417236328125
▁and 2.474609375
▁highlight 3.849609375
▁the 0.1600341796875
▁importance 2.302734375
▁of 0.0005707740783691406
▁continued 2.8984375
▁research 0.244140625
▁and 0.833984375
▁rig 2.76171875
orous 0.00412750244140625
▁testing 0.94970703125
. 0.662109375
▁While 1.306640625
▁initial 2.662109375
▁clin 2.78125
ical 0.00017404556274414062
▁results 2.568359375
▁are 0.49609375
▁und 4.71484375
ou 0.498779296875
bt 0.0006890296936035156
edly 0.0002715587615966797
▁prom 0.89306640625
ising 3.0159950256347656e-05
, 0.0048828125
▁anal 2.283203125
yst 0.0007071495056152344
s 0.0024738311767578125
▁under 6.16015625
line 0.0024662017822265625
▁the 0.216552734375
▁need 0.2257080078125
▁for 0.12335205078125
▁statistical 8.1875
▁significance 0.67724609375
▁and 0.455322265625
▁further 2.45703125
▁investig 5.20703125
ations 0.0123291015625
▁to 1.1708984375
▁subst 3.755859375
anti 1.621246337890625e-05
ate 3.8623809814453125e-05
▁the 0.308349609375
▁drug 0.57421875
' 0.00888824462890625
s 5.829334259033203e-05
▁effic 0.73046875
acy 2.2411346435546875e-05
▁beyond 4.66796875
▁the 0.98681640625
▁limited 3.505859375
▁sample 1.75
▁size 0.08843994140625
▁observed 5.10546875
▁so 2.4296875
▁far 2.86102294921875e-05
. 0.0048370361328125
▁Cont 7.45703125
in 0.201416015625
ued 0.004680633544921875
▁evalu 6.34375
ations 0.00215911865234375
▁of 2.681640625
▁long 3.244140625
- 0.0048065185546875
term 0.0006747245788574219
▁safety 1.8671875
, 2.595703125
▁potential 3.375
▁side 0.23046875
▁effects 0.023162841796875
, 0.1614990234375
▁and 0.034942626953125
▁the 2.7890625
▁drug 0.2373046875
' 0.006519317626953125
s 3.457069396972656e-05
▁effect 1.9384765625
iveness 0.1695556640625
▁against 1.302734375
▁different 0.9453125
▁cancer 1.5078125
▁types 0.04620361328125
▁are 0.2384033203125
▁cru 1.564453125
cial 0.00013959407806396484
▁before 1.490234375
▁drawing 3.283203125
▁any 1.4326171875
▁definit 0.56396484375
ive 3.159046173095703e-05
▁conclus 0.007747650146484375
ions 2.181529998779297e-05
. 0.0828857421875
<0x0A> 0.045196533203125
Address 7.05859375
ing 0.01529693603515625
▁H 5.796875
urd 0.36376953125
les 0.0006542205810546875
▁A 4.609375
head 0.0022830963134765625
: 0.0193328857421875
<0x0A> 0.00313568115234375
The 2.00390625
▁landscape 7.84765625
▁of 0.270751953125
▁cancer 0.08740234375
▁research 1.857421875
▁is 0.7158203125
▁l 3.2421875
itter 0.08056640625
ed 8.225440979003906e-06
▁with 0.000873565673828125
▁count 4.91796875
less 1.2993812561035156e-05
▁prom 1.34765625
ising 8.082389831542969e-05
▁ther 2.533203125
ap 0.0002410411834716797
ies 1.2516975402832031e-05
▁that 0.11553955078125
▁failed 1.357421875
▁to 0.08563232421875
▁deliver 1.5498046875
▁upon 4.2421875
▁further 5.89453125
▁exam 2.875
ination 0.041839599609375
. 0.187255859375
▁Anal 2.15234375
yst 0.00290679931640625
s 0.0009660720825195312
▁and 5.28125
▁industry 2.37890625
▁ins 2.369140625
iders 0.0004017353057861328
▁agree 3.59375
▁that 0.0245361328125
▁the 1.5478515625
▁road 2.533203125
▁ahead 0.6884765625
▁remains 2.294921875
▁challeng 0.72509765625
ing 9.644031524658203e-05
. 2.333984375
▁The 2.1015625
▁drug 0.8134765625
' 0.52294921875
s 6.80685043334961e-05
▁effic 2.2109375
acy 2.5510787963867188e-05
▁must 1.4541015625
▁be 0.07366943359375
▁demonstrated 2.408203125
▁across 1.9189453125
▁larger 3.287109375
▁patient 0.7509765625
▁coh 2.0859375
ort 1.430511474609375e-06
s 0.000492095947265625
▁to 3.037109375
▁determine 3.0390625
▁whether 2.431640625
▁the 1.1142578125
▁initial 2.41796875
▁success 3.091796875
▁stories 8.453125
▁can 1.599609375
▁be 0.036346435546875
▁rep 0.2493896484375
licated 0.0008864402770996094
▁consist 3.65234375
ently 0.00010800361633300781
. 0.255615234375
▁Furthermore 2.01953125
, 8.225440979003906e-05
▁regul 1.712890625
atory 0.047882080078125
▁appro 0.70849609375
val 2.5272369384765625e-05
▁processes 1.4658203125
, 2.228515625
▁pr 4.3359375
icing 0.00045228004455566406
▁challeng 5.91015625
es 9.894371032714844e-06
, 0.0110626220703125
▁and 0.0477294921875
▁access 1.509765625
▁to 2.52734375
▁the 2.248046875
▁treatment 2.7890625
▁for 1.859375
▁all 2.8046875
▁patients 0.927734375
▁will 2.88671875
▁require 1.3466796875
▁careful 1.880859375
▁consideration 0.45703125
. 0.6240234375
<0x0A> 0.1453857421875
Import 6.18359375
ance 0.033538818359375
▁of 0.0156402587890625
▁Coll 1.9814453125
abor 7.319450378417969e-05
ative 1.8779296875
▁E 0.3583984375
ff 3.5881996154785156e-05
ort 1.7404556274414062e-05
s 0.04156494140625
: 0.017669677734375
<0x0A> 0.00131988525390625
To 3.775390625
▁ensure 3.0234375
▁progress 4.8359375
▁in 0.86767578125
▁cancer 1.6806640625
▁research 0.3671875
, 0.254150390625
▁collabor 3.28515625
ative 0.118408203125
▁efforts 0.0966796875
▁among 1.8779296875
▁scient 1.9736328125
ists 0.00011622905731201172
, 0.056793212890625
▁medical 2.732421875
▁profession 0.23828125
als 2.300739288330078e-05
, 0.003978729248046875
▁regul 3.091796875
atory 0.669921875
▁bodies 0.62353515625
, 0.003993988037109375
▁and 0.1378173828125
▁fund 2.787109375
ing 0.0655517578125
▁ag 0.404296875
encies 5.435943603515625e-05
▁are 0.1468505859375
▁essential 1.0556640625
. 0.00832366943359375
▁A 4.01171875
▁un 2.8125
ited 1.8994140625
▁front 0.59326171875
▁allows 5.890625
▁for 0.1473388671875
▁the 0.943359375
▁highest 7.8671875
▁standards 1.4677734375
▁of 0.06781005859375
▁scr 4.8515625
ut 7.62939453125e-06
iny 0.0025196075439453125
, 1.0166015625
▁thus 7.43359375
▁mit 3.423828125
ig 7.867813110351562e-06
ating 0.0001825094223022461
▁any 3.078125
▁potential 0.469482421875
▁ris 0.521484375
ks 2.9802322387695312e-06
▁or 2.7734375
▁mis 2.369140625
inter 2.38671875
pret 0.0024585723876953125
ation 1.37109375
▁of 0.07733154296875
▁prom 6.46484375
ising 0.0006289482116699219
▁data 2.052734375
. 0.0679931640625
▁Anal 4.2578125
yst 0.00408935546875
s 0.0006093978881835938
▁assert 5.1328125
▁that 0.0968017578125
▁such 3.240234375
▁collabor 1.5302734375
ations 0.66357421875
▁will 1.5078125
▁be 1.4462890625
▁p 4.09765625
iv 1.6808509826660156e-05
otal 2.0265579223632812e-06
▁in 0.143798828125
▁navig 4.4921875
ating 1.5974044799804688e-05
▁the 0.1429443359375
▁complex 1.4150390625
▁journey 3.908203125
▁from 2.470703125
▁experimental 2.705078125
▁phases 6.19921875
▁to 0.04718017578125
▁approved 3.83984375
, 4.546875
▁accessible 1.265625
▁treat 0.89697265625
ments 9.059906005859375e-06
. 0.5634765625
<0x0A> 0.04632568359375
Pat 6.29296875
ient 0.37060546875
▁Imp 4.21484375
act 0.1434326171875
▁and 1.38671875
▁Future 2.134765625
▁Pers 4.03515625
pect 0.1097412109375
ives 9.810924530029297e-05
: 0.01446533203125
<0x0A> 0.0009260177612304688
Und 5.65625
ou 0.1795654296875
bt 7.867813110351562e-05
edly 5.7220458984375e-05
, 0.001434326171875
▁the 0.41064453125
▁potential 0.984375
▁break 1.62890625
through 0.00018143653869628906
▁in 2.541015625
▁cancer 0.10394287109375
▁treatment 0.310302734375
▁show 6.29296875
c 0.39013671875
ased 0.0004150867462158203
▁by 0.007122039794921875
▁[ 0.0182952880859375
Company 0.0034885406494140625
▁Name 0.003448486328125
] 0.00478363037109375
' 2.796875
s 0.00035071372985839844
▁drug 0.501953125
▁inst 9.453125
ig 2.236328125
ates 0.004474639892578125
▁hope 0.783203125
▁among 1.7578125
▁patients 0.50146484375
, 2.392578125
▁care 2.330078125
g 0.0221099853515625
ivers 7.808208465576172e-05
, 0.006023406982421875
▁and 0.0243072509765625
▁health 0.5966796875
care 0.0282135009765625
▁prov 1.5029296875
iders 1.1563301086425781e-05
▁world 1.8466796875
wide 0.0001024007797241211
. 0.003543853759765625
▁However 1.4306640625
, 0.0001043081283569336
▁anal 1.453125
yst 0.00046753883361816406
s 0.0006542205810546875
▁emphas 1.28515625
ize 0.0016546249389648438
▁the 0.75244140625
▁importance 1.2021484375
▁of 0.0008487701416015625
▁man 4.26953125
aging 0.00015425682067871094
▁expect 0.18603515625
ations 5.53131103515625e-05
▁while 2.033203125
▁understanding 5.2265625
▁that 0.83056640625
▁research 4.65625
▁and 0.9541015625
▁development 0.461669921875
▁in 3.078125
▁the 1.212890625
▁field 0.3134765625
▁of 0.3232421875
▁on 1.05078125
col 0.0018463134765625
ogy 1.6689300537109375e-05
▁is 1.349609375
▁an 1.52734375
▁intr 4.03125
icate 0.0124969482421875
▁process 1.3095703125
▁that 1.2099609375
▁requires 1.1494140625
▁time 1.4609375
▁and 0.751953125
▁careful 3.978515625
▁evaluation 2.34765625
. 0.1644287109375
▁Cont 5.265625
in 0.118896484375
ued 0.00635528564453125
▁support 3.91015625
▁and 0.77392578125
▁invest 1.0537109375
ments 2.46484375
▁in 0.462158203125
▁cutting 2.5546875
- 0.0009698867797851562
edge 0.00012981891632080078
▁research 1.15234375
, 3.1953125
▁couple 1.3525390625
d 2.384185791015625e-06
▁with 9.822845458984375e-05
▁a 2.044921875
▁patient 3.541015625
- 0.01678466796875
orient 5.28125
ed 0.0022945404052734375
▁approach 0.12164306640625
, 0.256591796875
▁will 1.08203125
▁be 0.98681640625
▁cru 0.95751953125
cial 4.0531158447265625e-06
▁to 2.15234375
▁capital 6.9765625
ize 0.9658203125
▁on 0.0095977783203125
▁the 0.66455078125
▁significant 4.546875
▁progress 1.3603515625
▁achieved 1.6259765625
▁and 3.126953125
▁ultimately 2.876953125
▁offer 4.953125
▁improved 4.328125
▁treatment 2.16015625
▁options 0.262939453125
▁to 0.767578125
▁cancer 1.4990234375
▁patients 0.042724609375
▁glob 1.7451171875
ally 4.76837158203125e-06
. 0.0081634521484375
<0x0A> 0.2431640625
Con 2.5546875
clusion 0.21435546875
: 0.06402587890625
<0x0A> 9.0390625
[ 4.37890625
Company 0.01506805419921875
▁Name 0.00452423095703125
] 0.0841064453125
' 0.06488037109375
s 0.0002918243408203125
▁cancer 1.607421875
▁drug 0.2498779296875
▁represents 2.21484375
▁an 2.248046875
▁exc 0.48876953125
iting 2.7418136596679688e-06
▁development 0.82080078125
▁in 0.1097412109375
▁the 0.1258544921875
▁battle 2.71875
▁against 0.002719879150390625
▁this 1.853515625
▁dev 0.5869140625
ast 7.867813110351562e-06
ating 0.000438690185546875
▁disease 0.06329345703125
. 0.11865234375
▁Although 3.57421875
▁initial 1.5302734375
▁clin 1.4990234375
ical 7.486343383789062e-05
▁tri 1.37890625
als 7.474422454833984e-05
▁have 0.83740234375
▁shown 2.27734375
▁great 5.66015625
▁promise 0.050384521484375
, 0.018157958984375
▁anal 0.8408203125
yst 0.0001919269561767578
s 0.00043320655822753906
▁stress 1.875
▁the 0.1517333984375
▁importance 1.302734375
▁of 0.00022399425506591797
▁pr 6.015625
ud 0.41796875
ence 0.0201416015625
▁and 0.2313232421875
▁further 1.279296875
▁investigation 2.126953125
▁before 0.2396240234375
▁making 3.248046875
▁confident 7.55859375
▁claims 1.0400390625
▁about 0.68896484375
▁the 0.411376953125
▁drug 0.09234619140625
' 0.005474090576171875
s 5.14984130859375e-05
▁effic 0.41845703125
acy 1.9788742065429688e-05
. 0.288818359375
▁As 2.744140625
▁the 0.89404296875
▁medical 3.3125
▁community 0.193359375
▁moves 3.537109375
▁forward 0.34375
, 0.626953125
▁on 4.9140625
going 0.10272216796875
▁collabor 1.4072265625
ations 0.7578125
, 1.6279296875
▁rig 2.78515625
orous 0.002544403076171875
▁testing 1.0712890625
, 0.1610107421875
▁and 0.0126800537109375
▁thorough 7.03125
▁evaluation 1.8251953125
▁will 0.390625
▁play 4.265625
▁a 0.250732421875
▁vital 1.9580078125
▁role 0.0028285980224609375
▁in 0.0028781890869140625
▁transform 3.779296875
ing 0.00033736228942871094
▁a 7.6953125
▁potential 1.2998046875
▁break 0.0127105712890625
through 9.1552734375e-05
▁into 0.01389312744140625
▁a 0.53759765625
▁genu 4.3125
ine 0.11968994140625
▁life 3.87109375
- 0.005596160888671875
s 0.345947265625
aving 0.0004017353057861328
▁treatment 0.66748046875
▁for 0.82861328125
▁cancer 0.223876953125
▁patients 0.005153656005859375
▁world 0.58056640625
wide 5.1021575927734375e-05
. 0.0089569091796875
